Gilead Sciences Inc (GILD) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition o...
Gilead Sciences Inc's revenue increased 2.4% year over year, from $28.75B to $29.44B.
Net income increased 1672.9% over the same period, from $480.0M to $8.51B.
Over the 9-year period from FY2016 to FY2025, revenue declined by 3% in total.
Total debt decreased by 6.6% to $24.94B.
The debt-to-equity ratio stands at 1.10, indicating a elevated leverage profile.
Operating cash flow declined 7.5% to $10.02B.
Gilead Sciences Inc maintains a strong net profit margin of 28.9%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $7.54B+8.5% | $1.25B | $5.97B | $888.0M | $4.31B | $54.52B | $23.25B | $18.48B |
| Q4 FY2024 | $7.57B+0.3% | $1.78B | $5.99B | $2.45B | $2.98B | $58.99B | $26.71B | $19.33B |
| Q1 FY2025 | $6.67B-11.9% | $1.31B | $5.13B | $2.24B | $1.76B | $56.43B | $24.95B | $19.16B |
| Q2 FY2025 | $7.08B+6.2% | $1.96B | $5.58B | $2.47B | $827.0M | $55.72B | $24.95B | $19.67B |
| Q3 FY2025 | $7.77B+9.7% | $3.05B | $6.20B | $3.33B | $4.11B | $58.53B | $24.94B | $21.54B |
| Q4 FY2025 | $7.92B+2.0% | $2.18B | $6.30B | $1.98B | $3.33B | $59.02B | $24.94B | $22.70B |
| Q1 FY2026 | $6.96B-12.2% | $2.02B | $5.51B | $2.59B | $2.54B | N/A | N/A | N/A |
| Q2 FY2026 | $7.80B+12.1% | $-10.50B | $6.22B | $-10.39B | $3.57B | N/A | N/A | N/A |
Balance Sheet Summary (FY2025)
Gilead Sciences Inc (GILD) Financial Statements & Revenue History
Gilead Sciences Inc (GILD) is a US-listed stock operating in the Healthcare sector, specifically the Biotechnology industry trading at $156.84 with a market capitalization of $194. This page provides 42 historical financial statements for Gilead Sciences Inc, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Gilead Sciences Inc reported revenue of $29.4 billion, representing 2.4% year-over-year growth. The net profit margin of 28.9% reflects strong profitability. The debt-to-equity ratio of 1.10 indicates elevated leverage.
GILD Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Gilead Sciences Inc's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether GILD is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track GILD's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Gilead Sciences Inc converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of GILD's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use GILD Financial Data
Investors use Gilead Sciences Inc's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare GILD's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how GILD's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View GILD's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Gilead Sciences Inc's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.GILD trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.